ArticleFrontiers in oncology2022
Establishment and Validation of Pre-Therapy Cervical Vertebrae Muscle Quantification as a Prognostic Marker of Sarcopenia in Patients With Head and Neck Cancer.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- From neck to abdomen: cervical (C3) muscle quantification as a surrogate to lumbar (L3) sarcopenia assessment in head and neck cancer: systematic review and meta-analysis.Skeletal radiology · 2026Pooled it
- Fatigue in head and neck cancer survivors after radiotherapy - prevalence, risk factors, and radiation dose correlates.Journal of cancer survivorship : research and practice · 2026Article
- Sarcopenia is associated with poor swallowing outcomes after resection and free flap reconstruction for oral cancer.Oral oncology reports · 2026Article
- Article
- Article
- Sarcopenia as a prognostic factor in head and neck squamous cell carcinoma: a systematic review and meta-analysis.European radiology · 2026Article
- Clinical impact of computed tomography-measured skeletal muscle status at the third cervical vertebra on definitive radiotherapy outcomes for head and neck squamous cell carcinoma.Japanese journal of radiology · 2026Article
- Article
- Article
- Development and Validation of an Automated Image-Based Deep Learning Platform for Sarcopenia Assessment in Head and Neck Cancer.JAMA network open · 2023Article
- Fully-automated sarcopenia assessment in head and neck cancer: development and external validation of a deep learning pipeline.medRxiv : the preprint server for health sciences · 2023Article
- The impact of sarcopenia on survival and treatment tolerance in patients with head and neck cancer treated with chemoradiotherapy.Cancer medicine · 2023Observational
- Muscle and adipose tissue segmentations at the third cervical vertebral level in patients with head and neck cancer.Scientific data · 2022Article
- Deep learning auto-segmentation of cervical skeletal muscle for sarcopenia analysis in patients with head and neck cancer.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundSarcopenia is prognostic for survival in patients with head and neck cancer (HNC). However, identification of this high-risk feature remains challenging without computed tomography (CT) imaging of the abdomen or thorax. Herein, we establish sarcopenia thresholds at the C3 level and determine if C3 sarcopenia is associated with survival in patients with HNC.
methodsThis retrospective cohort study was conducted in consecutive patients with a squamous cell carcinoma of the head and neck with cross-sectional abdominal or neck imaging within 60 days prior to treatment. Measurement of cross-sectional muscle area at L3 and C3 levels was performed from CT imaging. Primary study outcome was overall survival.
resultsSkeletal muscle area at C3 was strongly correlated with the L3 level in both men (n = 188; r = 0.77; p < 0.001) and women (n = 65; r = 0.80; p < 0.001), and C3 sarcopenia thresholds of 14.0 cm
conclusionsThis study identifies sarcopenia thresholds at the C3 level that best predict L3 sarcopenia in men and women. In HNC, C3-defined sarcopenia is associated with poor survival outcomes in men, but not women, suggesting sarcopenia may differentially affect men and women with HNC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.